|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:brand
|
gptkb:Revatio
gptkb:sildenafil
|
|
gptkbp:CASNumber
|
139755-83-2
|
|
gptkbp:chemicalFormula
|
C22H30N6O4S
|
|
gptkbp:color
|
blue
|
|
gptkbp:commonDosage
|
100 mg
25 mg
50 mg
|
|
gptkbp:contraindication
|
nitrate medication
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer_scientists
|
|
gptkbp:eliminationRoute
|
urine
feces
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:halfLife
|
4 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Viagra
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
nitrates
alpha-blockers
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
PDE5 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
gptkb:women
children
|
|
gptkbp:originallyStudiedFor
|
angina
|
|
gptkbp:overdoseSymptoms
|
prolonged erection
vision changes
|
|
gptkbp:patentExpired
|
2013
|
|
gptkbp:pregnancyCategory
|
N (Not for use in women)
|
|
gptkbp:prescribes
|
adult males
|
|
gptkbp:prescriptionDrugClass
|
phosphodiesterase inhibitors
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:riskFactor
|
priapism
sudden hearing loss
sudden vision loss
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
dyspepsia
flushing
visual disturbance
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:tabletShape
|
gptkb:jewelry
|
|
gptkbp:usedFor
|
erectile dysfunction
pulmonary arterial hypertension (as Revatio)
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
|
|
gptkbp:bfsLayer
|
4
|